-
公开(公告)号:US20110208300A1
公开(公告)日:2011-08-25
申请号:US12897131
申请日:2010-10-04
IPC分类号: A61F2/14
CPC分类号: A61F9/007 , A61F2/142 , A61F2/1451 , A61F2/1453 , A61F9/0017 , A61F2250/0019
摘要: A corneal only is configured to adhere to the cornea so as to inhibit epithelial growth under the onlay. Structures can be provided on the onlay to adhere the onlay to the eye. At least one of an epithelial layer or the water inhibiting layer can be provided on or over the onlay, for example a natural epithelial layer or water inhibiting layer that inhibits, for example minimizes, water penetration into the onlay, so as to adhere the onlay to the eye with pumping of the endothelium. The water inhibiting layer may comprise a therapeutic covering positioned over the onlay to inhibit swelling of the cornea. The posterior surface of the onlay may be shaped so as to fit the anterior exposed surface of the cornea.
摘要翻译: 角膜仅被配置成粘附在角膜上,以便抑制覆盖物下的上皮生长。 可以在镶嵌上提供结构以将贴面粘附到眼睛上。 上皮层或水分抑制层中的至少一个可以设置在覆盖物上或上方,例如天然上皮层或水分抑制层,其抑制例如使水渗入到镶嵌物中的最小程度,以便粘附该覆盖层 通过泵送内皮到眼睛。 防水层可以包括定位在覆层上的治疗覆盖物,以抑制角膜的肿胀。 垫片的后表面可以被成形为适合角膜的前暴露表面。
-
公开(公告)号:US20100036488A1
公开(公告)日:2010-02-11
申请号:US12384659
申请日:2009-04-06
申请人: Eugene de Juan, JR. , Cary J. Reich , Stephen Boyd , Yair Alster , David Sierra , Hanson S. Gifford , Jose D. Alejandro , Richard L. Lindstrom , K. Angela Macfariane , Douglas Sutton , John Anthony
发明人: Eugene de Juan, JR. , Cary J. Reich , Stephen Boyd , Yair Alster , David Sierra , Hanson S. Gifford , Jose D. Alejandro , Richard L. Lindstrom , K. Angela Macfariane , Douglas Sutton , John Anthony
IPC分类号: A61F2/14
CPC分类号: A61F2/142 , A61F2/14 , A61F9/00 , A61F2250/0067 , G02C7/047
摘要: A therapeutic lens for the treatment of an epithelial defect comprises a layer of therapeutic material disposed over the stroma and/or Bowman's membrane to inhibit water flow from the tear liquid to the stroma and/or Bowman's membrane, such that corneal deturgescence can be restored to decrease corneal swelling and light scattering. The layer may cover and protect nerve fibers to decrease pain. The layer may comprise an index of refraction to inhibit light scatter from an anterior surface of the stroma and/or Bowman's membrane. The lens may comprise a curved anterior surface that provides functional vision for the patient when the epithelium regenerates. The layer of therapeutic material can be positioned on the eye in many ways, for example with a spray that is cured to adhere the layer to the exposed surface of the stroma and/or Bowman's membrane.
摘要翻译: 用于治疗上皮缺损的治疗镜片包括设置在基质和/或Bowman膜上的治疗材料层,以抑制从泪液到基质和/或Bowman膜的水流,使得可以恢复角膜deturgescence 减少角膜肿胀和光散射。 该层可以覆盖并保护神经纤维以减轻疼痛。 该层可以包括折射率以抑制从基质和/或Bowman膜的前表面的光散射。 透镜可以包括弯曲的前表面,当上皮再生时,该前表面为患者提供功能视觉。 治疗材料层可以以许多方式定位在眼睛上,例如通过固化以将该层粘附到基质和/或Bowman膜的暴露表面上的喷雾。
-
公开(公告)号:US20120136322A1
公开(公告)日:2012-05-31
申请号:US13151001
申请日:2011-06-01
申请人: Yair Alster , Eugene de Juan, JR. , Cary J. Reich , Stephen Boyd , David Sierra , Jose D. Alejandro , K. Angela Macfarlane , Douglas Sutton
发明人: Yair Alster , Eugene de Juan, JR. , Cary J. Reich , Stephen Boyd , David Sierra , Jose D. Alejandro , K. Angela Macfarlane , Douglas Sutton
CPC分类号: A61F9/0026 , A61F9/0017 , A61K9/0051 , A61K31/19 , A61K31/335 , A61K31/407 , A61K31/4178 , A61K31/43 , A61K31/5377 , A61K31/5415 , A61K31/55 , A61K31/557 , A61K31/5575 , A61K31/56 , A61K31/568 , A61K31/573 , A61K31/58 , A61K31/7036 , A61K38/00 , A61M31/002
摘要: A therapeutic system comprises an ocular insert placed on a region outside an optical zone of an eye. The ocular insert comprises two structures: a first skeletal structure and a second cushioning structure. The first structure functions as a skeletal frame which maintains positioning of the implant along the anterior portion of the eye and provides support to the second, cushioning structure. This first structure maintains the attachment of the therapeutic system to the anterior portion of the eye for at least thirty days. In some embodiments the first structure remains a constant size and shape, e.g. a ring shape, a ring with haptics, or a curvilinear ring that is confined to and restrainingly engages the inferior and superior conjunctival fornices so as to retain the implant within the tear fluid and/or against the tissues of the eye.
摘要翻译: 治疗系统包括放置在眼睛的光学区域外的区域上的眼部插入物。 眼睛插入件包括两个结构:第一骨架结构和第二缓冲结构。 第一结构用作骨架框架,其保持沿着眼睛前部的植入物的定位,并向第二缓冲结构提供支撑。 该第一结构将治疗系统的附着维持在眼前部至少三十天。 在一些实施例中,第一结构保持恒定的尺寸和形状,例如。 环形,具有触觉的环或曲线环,其限制并限制性地接合下部和上结膜,以将植入物保持在泪液和/或针对眼睛的组织。
-
公开(公告)号:US20150133878A1
公开(公告)日:2015-05-14
申请号:US14600505
申请日:2015-01-20
申请人: Eugene de Juan, JR. , Yair Alster , Cary J. Reich , K. Angela MacFarlane , Janelle Chang , Stephen Boyd , David Sierra , Jose D. Alejandro , Douglas Sutton , Alexander J. Gould
发明人: Eugene de Juan, JR. , Yair Alster , Cary J. Reich , K. Angela MacFarlane , Janelle Chang , Stephen Boyd , David Sierra , Jose D. Alejandro , Douglas Sutton , Alexander J. Gould
CPC分类号: A61F9/0017 , A61B17/00234 , A61K9/0051 , A61K47/34 , A61L27/025 , A61L27/16
摘要: A comfortable insert comprises a retention structure sized for placement under the eyelids and along at least a portion of conjunctival sac of the upper and lower lids of the eye. The retention structure resists deflection when placed in the conjunctival sac of the eye and to guide the insert along the sac when the eye moves. The retention structure can be configured in many ways to provide the resistance to deflection and may comprise a hoop strength so as to urge the retention structure outward and inhibit movement of the retention structure toward the cornea. The insert may move rotationally with deflection along the conjunctival sac, and may comprise a retention structure having a cross sectional dimension sized to fit within folds of the conjunctiva. The insert may comprise a release mechanism and therapeutic agent to release therapeutic amounts of the therapeutic agent for an extended time.
摘要翻译: 舒适的插入物包括保持结构,其尺寸适于放置在眼睑下方并且沿着眼睛的上盖和下盖的结膜囊的至少一部分。 保留结构在放置在眼结膜囊中时抵抗偏转,并且当眼睛移动时沿着囊引导插入物。 保持结构可以以许多方式构造以提供对偏转的抵抗力,并且可以包括环箍强度,以便向外推动保持结构并阻止保持结构朝向角膜的移动。 插入件可以沿着结膜囊的偏转而旋转移动,并且可以包括保持结构,该保持结构具有尺寸适合于结膜折叠的横截面尺寸。 插入物可以包含释放机制和治疗剂以释放长期治疗剂的治疗剂量。
-
公开(公告)号:US20130066283A1
公开(公告)日:2013-03-14
申请号:US13503841
申请日:2010-10-22
申请人: Yair Alster , Hanson S. Gifford , Cary J. Reich , Eugene de Juan, JR. , John A. Scholl , Jose D. Alejandro , Douglas Sutton , Omer Rafaeli
发明人: Yair Alster , Hanson S. Gifford , Cary J. Reich , Eugene de Juan, JR. , John A. Scholl , Jose D. Alejandro , Douglas Sutton , Omer Rafaeli
IPC分类号: A61F9/01
CPC分类号: A61F9/008 , A61B18/02 , A61F9/0079 , A61F9/00804 , A61F9/009 , A61F2009/00872 , A61F2009/00893 , A61N1/36021 , A61N1/36046 , A61N1/40 , A61N7/02
摘要: Methods and apparatus for the treatment of the eye to reduce pain can treat at least an outer region of the tissue so as to denervate nerves extending into the inner region and reduce the pain. For example, the cornea of the eye may comprise an inner region having an epithelial defect, and an outer portion of the cornea can be treated to reduce pain of the epithelial defect. The outer portion of the cornea can be treated to denervate nerves extending from the outer portion to the inner portion. The outer portion can be treated in many ways to denervate the nerve, for example with one or more of heat, cold or a denervating noxious substance such as capsaicin. The denervation of the nerve can be reversible, such that corneal innervation can return following treatment.
摘要翻译: 用于治疗眼睛以减轻疼痛的方法和装置可以治疗组织的至少外部区域,以便使延伸到内部区域的神经衰老,并减轻疼痛。 例如,眼睛的角膜可以包括具有上皮缺损的内部区域,并且可以治疗角膜的外部部分以减少上皮缺损的疼痛。 角膜的外部可以被处理以将从外部延伸到内部部分的神经去激活。 外部部分可以以许多方式被治疗以使神经变性,例如用一种或多种热,冷或去神经感染的有害物质如辣椒素。 神经的去神经可以是可逆的,使得角膜神经支配可以在治疗后返回。
-
公开(公告)号:US20130090612A1
公开(公告)日:2013-04-11
申请号:US13688019
申请日:2012-11-28
申请人: Eugene de Juan, JR. , Yair Alster , Cary J. Reich , K. Angela MacFarlane , Janelle Chang , Jose D. Alejandro
发明人: Eugene de Juan, JR. , Yair Alster , Cary J. Reich , K. Angela MacFarlane , Janelle Chang , Jose D. Alejandro
IPC分类号: A61F9/00
CPC分类号: A61F9/0017 , A61B17/00234 , A61K9/0051 , A61K47/34 , A61L27/025 , A61L27/16
摘要: A comfortable insert comprises a retention structure sized for placement under the eyelids and along at least a portion of conjunctival sac of the upper and lower lids of the eye. The retention structure resists deflection when placed in the conjunctival sac of the eye and to guide the insert along the sac when the eye moves. The retention structure can be configured in many ways to provide the resistance to deflection and may comprise a hoop strength so as to urge the retention structure outward and inhibit movement of the retention structure toward the cornea. The insert may move rotationally with deflection along the conjunctival sac, and may comprise a retention structure having a cross sectional dimension sized to fit within folds of the conjunctiva. The insert may comprise a release mechanism and therapeutic agent to release therapeutic amounts of the therapeutic agent for an extended time.
-
公开(公告)号:US20090099626A1
公开(公告)日:2009-04-16
申请号:US12231987
申请日:2008-09-05
申请人: Eugene de Juan, JR. , Stephen Boyd , Cary J. Reich , Christopher V. Cardenas , Tommy Jewell , Lorrie Ma , Ngoc-Tuan Nguyen
发明人: Eugene de Juan, JR. , Stephen Boyd , Cary J. Reich , Christopher V. Cardenas , Tommy Jewell , Lorrie Ma , Ngoc-Tuan Nguyen
CPC分类号: A61F9/0017 , A61B5/0031 , A61B5/06 , A61B5/411 , A61B8/0833 , A61B2562/08 , A61F9/00772 , A61F2250/0068 , A61F2250/0096 , A61L31/043 , A61L31/044 , A61L31/06 , A61L31/145 , A61L31/16 , A61L2300/404 , A61L2300/43 , G01R33/0213 , G01R33/072
摘要: This document discusses, among other things, an apparatus comprising a lacrimal implant insertable at least partially into a lacrimal punctum. The lacrimal implant comprises an implant core, and an implant body. The implant body includes a cavity sized and shaped to receive the implant core. At least one of the implant core and the implant cavity includes a detection device configured to allow automatic detection of the lacrimal implant with a separate detector device.
摘要翻译: 该文件尤其涉及一种包括可以至少部分地插入泪点的泪道植入物的装置。 泪管植入物包括植入物芯和植入体。 植入体包括尺寸和形状以容纳植入物芯的腔体。 植入物芯和植入腔中的至少一个包括检测装置,其被配置为允许用单独的检测器装置自动检测泪道植入物。
-
公开(公告)号:US20090104243A1
公开(公告)日:2009-04-23
申请号:US12231986
申请日:2008-09-05
申请人: Deepank Utkhede , Robert W. Shimizu , Rachna Jain , Stephen Boyd , Hanson S. Gifford , Eugene de Juan, JR. , Cary J. Reich
发明人: Deepank Utkhede , Robert W. Shimizu , Rachna Jain , Stephen Boyd , Hanson S. Gifford , Eugene de Juan, JR. , Cary J. Reich
CPC分类号: A61K9/0051 , A61F9/0017 , A61F9/00772 , A61F2230/0069 , A61F2250/0067 , A61K31/5575 , A61K47/34 , A61L27/54 , A61L2300/41 , A61L2300/602 , A61L2300/802 , Y02A50/395
摘要: A solid drug core insert can be manufactured by injecting a liquid mixture comprising a therapeutic agent and a matrix precursor into a sheath body. The injection can be conducted at subambient temperatures. The mixture is cured to form a solid drug-matrix core. The therapeutic agent can be a liquid at about room temperature that forms a dispersion of droplets in the matrix material. A surface of the solid drug core is exposed, for example by cutting the tube, and the exposed surface of the solid drug core releases therapeutic quantities of the therapeutic agent when implanted into the patient. In some embodiments, the insert body inhibits release of the therapeutic agent, for example with a material substantially impermeable to the therapeutic agent, such that the therapeutic quantities are released through the exposed surface, thereby avoiding release of the therapeutic agent to non-target tissues.
摘要翻译: 可以通过将包含治疗剂和基质前体的液体混合物注入鞘体来制造固体药物核心插入物。 注射可以在低于环境温度下进行。 将混合物固化以形成固体药物基质核心。 治疗剂可以是在约室温下的液体,其形成液滴在基质材料中的分散体。 固体药物核心的表面例如通过切割管而暴露,并且固体药物核心的暴露表面在植入患者体内释放治疗剂量。 在一些实施方案中,插入体抑制治疗剂的释放,例如具有对治疗剂基本上不可渗透的材料,使得治疗量通过暴露表面释放,从而避免将治疗剂释放到非靶组织 。
-
公开(公告)号:US20100114309A1
公开(公告)日:2010-05-06
申请号:US12521543
申请日:2007-12-21
IPC分类号: A61F2/16
CPC分类号: A61F9/0017 , A61F9/00772 , A61F9/00781 , A61K9/0051
摘要: An implant for use with an eye comprises an implantable structure and a therapeutic agent. The therapeutic agent is deliverable from the structure into the eye so as to therapeutically effect and/or stabilize a refractive property of the eye. In many embodiments, the refractive property of the eye may comprise at least one of myopia, hyperopia or astigmatism. The therapeutic agent can comprise a composition that therapeutically effects or stabilizes the refractive property of the eye. The therapeutic agent may comprise at least one of a mydriatic or a cycloplegic drug. For example, the therapeutic agent may include a cycloplegic that comprises at least one of atropine, cyclopentolate, succinylcholine, homatropine, scopolamine, or tropicamide. In many embodiments, a retention element can be attached to the structure to retain the structure along a natural tissue surface.
摘要翻译: 用于眼睛的植入物包括可植入结构和治疗剂。 治疗剂可以从结构递送到眼睛中,以便治疗影响和/或稳定眼睛的折射性质。 在许多实施例中,眼睛的屈光性可以包括近视,远视或散光中的至少一种。 治疗剂可以包含治疗影响或稳定眼睛的折射性质的组合物。 治疗剂可以包括散瞳剂或瘫痪药物中的至少一种。 例如,治疗剂可以包括睫状肌麻痹症,其包括阿托品,环戊二酸酯,琥珀酰胆碱,同质素,东莨菪碱或托品酰胺中的至少一种。 在许多实施例中,保持元件可以附接到结构以沿着天然组织表面保持结构。
-
公开(公告)号:US20140358125A1
公开(公告)日:2014-12-04
申请号:US14236863
申请日:2012-08-03
申请人: Eugene de Juan, JR. , Yair Alster , Kathleen Cogan Farinas , K. Angela MacFarlane , Cary J. Reich , Randolph E. Campbell , Signe Erickson
发明人: Eugene de Juan, JR. , Yair Alster , Kathleen Cogan Farinas , K. Angela MacFarlane , Cary J. Reich , Randolph E. Campbell , Signe Erickson
IPC分类号: A61F9/00 , A61K31/382
CPC分类号: A61F9/0017 , A61F2250/0031 , A61F2250/0068 , A61K9/0051 , A61K31/382 , A61K31/407 , A61K31/519 , F04C2270/041
摘要: A therapeutic device that can release a therapeutic agent comprising a porous structure coupled to a container comprising a reservoir. The reservoir can comprise a volume sized to release therapeutic amounts of the therapeutic agent for an extended time when coupled to the porous structure and implanted in a patient. The porous structure may comprise a first side coupled to the reservoir and a second side to couple to the patient to release the therapeutic agent. The length of the channels extending from the first side to the second side may comprise an effective length greater than a distance across the porous structure from the first side to the second side. The therapeutic device may comprise a penetrable barrier to inject therapeutic agent into the device when implanted in the patient.
摘要翻译: 一种能够释放治疗剂的治疗装置,所述治疗剂包括与包含储存器的容器相连的多孔结构。 贮存器可以包含一定量的体积,当耦合到多孔结构并且植入患者体内时,释放处理量的治疗剂延长时间。 所述多孔结构可以包括联接到所述储存器的第一侧和与所述患者联接以释放所述治疗剂的第二侧。 从第一侧延伸到第二侧的通道的长度可以包括大于多孔结构从第一侧到第二侧的距离的有效长度。 治疗装置可以包括当植入患者时将治疗剂注射到装置中的可穿透屏障。
-
-
-
-
-
-
-
-
-